Transnational Pharmaceutical Enterprises Shift Focus to R&D Investment in China

Transnational pharmaceutical enterprises have shown a significant shift in their investment strategies, prioritizing research and development (R&D) in China since the country's accession to the World Trade Organization (WTO) in 2002. Currently, the world's top 20 transnational pharmaceutical enterprises have established joint venture plants in China, with some owning solely-funded enterprises. Despite China's growing market and abundant scientific and technological talent, intellectual property concerns have hindered investment decisions. Recent announcements, such as AstraZeneca's $100 million investment in medicine R&D and the establishment of an innovation center, indicate a growing trend of transnational pharmaceutical enterprises expanding their R&D presence in China.

Key Takeaways:

• Transnational pharmaceutical enterprises are increasing their investment in R&D in China, with the world's top 20 enterprises having established joint venture plants in the country.
• AstraZeneca's $100 million investment in medicine R&D and the establishment of an innovation center is the largest investment by a transnational pharmaceutical enterprise in R&D in China to date.
• Several transnational pharmaceutical enterprises, including Novartis and Wyeth, have launched plans to expand their investment in R&D and build R&D centers in China.
• The cautious attitude of transnational pharmaceutical enterprises towards investment in R&D in China reflects concerns about intellectual property protection.
• China's growing market and abundant scientific and technological talent are major attractions for transnational pharmaceutical enterprises.
• Companies such as NovoNordisk, AstraZeneca, Eli Lilly, and Roche have established R&D centers or branches in China, with Pfizer setting up an R&D center in Shanghai last year.

Statistics:

• Of China's top 500 foreign-funded enterprises, pharmaceutical enterprises account for 14.
• The world's top 20 transnational pharmaceutical enterprises have established joint venture plants in China.
• AstraZeneca's $100 million investment in medicine R&D is the largest single investment by a transnational pharmaceutical enterprise in R&D in China.
• NovoNordisk, headquartered in Denmark, has built a small R&D center in Beijing, its sole R&D branch outside of Denmark.

Sources:

• "XIC" (Xinhua International News), "AstraZeneca to invest $100 million in China's R&D", June 5, Asia Pulse.
• Various reports and announcements from transnational pharmaceutical enterprises, including AstraZeneca, Novartis, Wyeth, Pfizer, and others.